Leukemia (2018) 32, 462–469 www.nature.com/leu OPEN ORIGINAL ARTICLE The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms H Zhan1,2, CHS Lin2, Y Segal1 and K Kaushansky2,3 The acquired kinase mutation JAK2V617F plays a central role in ...
There was no difference in TGF-β1 mRNA expression according to the presence or absence of Jak2V617F mutation. In immunofluorescence staining, most fibrocytes that were differentiated from BMCs in vitro produced TGF-β1 (Fig. 6d). We next examined the secreted TGF-β1 from fibrocytes. Jak2V6...
We next assessed RECQL5 levels following JAK2 inhibition in two independent cell lines that harbor the JAK2V617F mutation: HEL and SET-2 cells. We found that treatment of the erythroleukemic cell line HEL and the megakaryoblastic cell line SET-2 with the JAK2 inhibitor INCB018424 reduced ...
Western immunoassay. This disparity may be explained by that JAK2V617F expression in our study was more consistent with heterozygous JAK2V617F mutation in essential thrombocythemia (ET) patients because endogenousJAK2gene was still present. The polycythemia vera (PV) patients usually carry homozygous...
CALRmutations had not been routinely investigated in patients suspected of MPN in our centre, as they have only recently been discovered1,2. In contrast, theJAK2V617F mutation has already been analysed routinely since its discovery in 200520. Therefore,JAK2V617F-positive patients were excluded ...
A single mutation V617F of JAK2 is seen in more than 90% of patients with polycythemia vera and in nearly 50% of patients with primary myelofibrosis and essential thrombocythemia11,12,13. This mutation leads to constitutive activation of JAK213, which is sufficient to drive myeloproliferative ...
In 2005, a gain-of-function somatic JAK2 mutation, V617F, was identified to be highly prevalent in myeloproliferative disorders4. Patients with this gain-of-function mutation have frequently been identified in polycythemia vera (PV; 95%), essential thrombocythemia (ET; 20–40%), and primary...
(megakaryoblastic cell line), which bear theJAK2V617Fmutation that constitutively activates the JAK2 signalling pathway. HSP27 depletion by the three different approaches affected cell proliferation induced by the constitutively activatedJAK2mutant (Fig.3a, Supplementary Fig.2a, b), but not apoptosis ...
(signal transducer and activator of transcription) signaling, spleen size, JAK2V617Fmutation burden, as well as levels of certain cytokines/growth factors relevant in MPNs. Nuclear JAK2 has been reported to have a second, epigenetic function that might contribute to leukemogenesis.13The JAK-family ...
The JAK2V617F mutation plays a major role in the pathogenesis of myeloproliferative neoplasms and is found in the vast majority of patients suffering from polycythemia vera and in roughly every second patient suffering from essential thrombocythemia or f